BIOCIUS & Agilent Technologies Launch High-throughput, RapidFire Accurate Mass Solution for Drug Discovery

The latest addition to the RapidFire portfolio, the RF360 High Resolution system, will be on display in the BIOCIUS hospitality suite at the 58th Annual American Society for Mass Spectrometry Conference in Salt Lake City, Utah from May 23rd to May 27th. High resolution mass spectrometry coupled with the unparalleled sample preparation throughput of the RapidFire platform enables significant streamlining of in vitro ADME assays, said Can 'Jon' Özbal, Chief Operating Officer of BIOCIUS. Extending our partnership with Agilent Technologies, the leader in TOF mass spectrometry allows us to completely eliminate the bottleneck of developing test-compound specific mass spectrometry methods. This revolutionary approach to in vitro ADME has been demonstrated to reduce analysis time to a fraction of that of conventional methods while requiring a minimal amount of operator input.

RapidFire technology combined with TOF mass spectrometers enables a wide range of ADME assays, including drug-drug interaction, metabolic stability, Caco, PAMPA and others. When performing such assays with the RF360, a priori knowledge of the test compound is not required, as data is acquired in full scan TOF-MS mode. Post acquisition, the relevant data is extracted using RapidFire software, eliminating the time consuming and labor-intensive steps of LC/MS method development and batch analysis.

Only TOF spectrometry can meet the scan speed and resolution demands required for these high-throughput types of applications, said Gustavo Salem, vice president and general manager of Agilent's Biological Systems Division. Partnering with BIOCIUS on the RF360 has provided a solution that is the fastest approach to ADME on the market.